Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
about
Approach to the Triple Negative Breast Cancer in New Drugs AreaNeoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureTargeted Therapies in Triple-Negative Breast CancerTriple negative breast cancer: looking for the missing link between biology and treatmentsPARP inhibitors in the management of breast cancer: current data and future prospectsThe role of taxanes in triple-negative breast cancer: literature reviewNeuraminidase-1: a novel therapeutic target in multistage tumorigenesisNovel therapeutic strategies for patients with triple-negative breast cancerMolecular Classification of Triple-Negative Breast CancerConcepts and targets in triple-negative breast cancer: recent results and clinical implicationsTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer paImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanesA phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialEfficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusChemotherapy in early breast cancer: when, how and which one?Predicting response and survival in chemotherapy-treated triple-negative breast cancer.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Familial breast cancer - targeted therapy in secondary and tertiary preventionTumor homologous recombination deficiency assays: another step closer to clinical application?Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysisLandscape of neoadjuvant therapy for breast cancerChemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers
P2860
Q26744054-F599D904-D8E9-4662-BF60-521D70218ACCQ26751249-F2D0081D-AEA4-44AA-B1BA-E4D9930F7C7EQ26777736-45BDE3DC-46E7-47D0-A8D2-E4DC3D845B92Q26783122-69406AB0-268E-4BD5-8AA8-8492D92CB4A2Q26798352-3C2A7BB5-B5B8-44DC-B1D4-4421B6069A7CQ26798356-0A678A43-26B3-4FD9-843C-09341B04EDD9Q28066130-822C3A23-7C39-42E3-98E0-2C2AE3DA8CACQ28067436-D8E550CC-2C1E-455C-8EF6-BFF9798989CCQ28076661-4422926C-598C-4B62-A73A-F2D64DDEE1B8Q28078992-11EE0862-24A1-469D-BA96-A491EA71C539Q28085062-8156997A-6BF0-409D-A7E0-81E139785E4BQ30313786-7206787E-51A5-4A79-83BE-705958BE8C88Q30315970-BC2BB4F3-C5F0-41A9-90E6-1F98E9AC8B8CQ30315973-4CBBDD85-DE1E-4F6D-9A97-B0BD8A54819DQ30316383-A11127E7-9C78-45B8-85C0-1E437F12D6F1Q31160308-3D8C1964-9587-491C-9FE6-D19898367D04Q33416887-52C8611E-4395-4518-BD0F-9065E66D7441Q33426722-0A78112E-AD22-4128-A194-39F8643F4465Q33430463-E2A87981-7D70-43C0-911B-E202534AE020Q33434092-8AF896EB-B856-4573-8F75-E8D750010332Q33438050-898193CC-27B6-45AC-80E0-A0F4E9F51C01Q33441772-C48DEE88-9A96-4CE7-BAAD-A5EBF3012F6DQ33728161-55329489-AE6B-4659-B785-FF11050E4DDBQ33769821-69B93576-0D9E-48F8-B37C-037A5977828EQ33887682-3EFB1539-E555-4345-B8A6-A7B34B6999E9Q33915057-69756E73-FC46-4EA8-A320-671688D8770BQ34038170-F9CB6079-1381-421D-AAD6-6710A69CC566Q34042640-E32B43E2-67B0-402D-B350-95DAAC756458Q34354538-954503FB-FB33-4AF4-B5F4-D80F13D4D945Q34476337-A0DF7424-2423-48D8-A796-8D6967B60913Q35119820-EE5F48D2-FE72-4FF9-8753-C255AAAF3531Q35180940-26A30FF2-619F-455F-82B5-3E71F422DAE7Q35399626-92949D84-34C1-45C9-AE96-B600C846007EQ35664732-F30F3D30-F3DA-4900-AF4C-7E09E03EB329Q35671356-7584DE84-5782-469B-8EBD-5021A9A38B2BQ35689902-62033824-A1BB-4235-8DAB-57982C39387EQ35753848-A4F3855D-E532-4EA8-8812-F1697A8A4A43Q35794915-30DD6CF7-91ED-4E13-B2A6-00DF2524496FQ35815486-E7B69CE4-587D-4CE1-913D-6AA20C7B4E1FQ35816698-43AEFAE9-76CF-4613-8E33-952C655E870D
P2860
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@ast
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@en
type
label
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@ast
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@en
prefLabel
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@ast
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@en
P2093
P50
P1433
P1476
Neoadjuvant carboplatin in pat ...... ): a randomised phase 2 trial.
@en
P2093
Bernd Gerber
Bruno V Sinn
Christian Jackisch
Christoph Salat
Claus Hanusch
Dirk M Zahm
Fariba Khandan
Hans Tesch
Jens U Blohmer
Jörn Hilfrich
P304
P356
10.1016/S1470-2045(14)70160-3
P50
P577
2014-04-30T00:00:00Z